Aerie Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference

DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retinal diseases and other diseases of the eye today announced
that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer,
will present at the Jefferies 2019 Healthcare Conference on Tuesday,
June 4, 2019 at 2:30 p.m. Eastern Time in New York, NY. Dr. Anido will
provide an Aerie overview and provide a business update.

The presentation will be webcast live and may be accessed by visiting
Aerie’s website at http://investors.aeriepharma.com.
A replay of the webcast will be available for 10 business days.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery,
development and commercialization of first-in-class therapies for the
treatment of patients with open-angle glaucoma, retinal diseases and
other diseases of the eye. Aerie’s first product, Rhopressa^® (netarsudil
ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S.
Food and Drug Administration (FDA) for the reduction of elevated
intraocular pressure (IOP) in patients with open-angle glaucoma or
ocular hypertension, was launched in the United States in April 2018. In
clinical trials of Rhopressa^®, the most common adverse
reactions were conjunctival hyperemia, corneal verticillata,
instillation site pain, and conjunctival hemorrhage. More information
about Rhopressa^®, including the product label, is available
at www.rhopressa.com.
Aerie’s second product for the reduction of elevated IOP in patients
with open-angle glaucoma or ocular hypertension, Rocklatan^® (netarsudil
and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only
fixed-dose combination of Rhopressa^® and the
widely-prescribed PGA (prostaglandin analog) latanoprost, has been
approved by the FDA and was launched in the United States in the second
quarter of 2019. In clinical trials of Rocklatan^®, the most
common adverse reactions were conjunctival hyperemia, corneal
verticillata, instillation site pain, and conjunctival hemorrhage. More
information about Rocklatan^®, including the product label, is
available at www.rocklatan.com.
Aerie continues to focus on global expansion and the development of
additional product candidates and technologies in ophthalmology,
including for wet age-related macular degeneration and diabetic macular
edema. More information is available at www.aeriepharma.com.

Contacts

Media: Tad Heitmann 949-526-8747; [email protected]
Investors:
Ami Bavishi 908-947-3949; [email protected]